SCHEMBL3466475

SCHEMBL3466475

CN1CCN(c2cccc(C(=O)N3CCC(F)(c4ccccc4F)CC3)n2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B14 Q9BPX1 2/20 0.49
MAPK1 P28482 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
USP2 O75604 1/20 0.49
PRKCQ Q04759 1/20 0.40
HTR3E A5X5Y0 3/20 0.40
HTR3B O95264 3/20 0.40
HTR3A P46098 3/20 0.40
HTR3D Q70Z44 3/20 0.40
HTR3C Q8WXA8 3/20 0.40
HRH4 Q9H3N8 2/20 0.39
IRAK4 Q9NWZ3 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 2/20 0.37
GBA1 P04062 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4293288 0.99 HSD17B14 (0.48) HSD17B14MAPK1SMN1; SMN2USP2PRKCQ
SCHEMBL3467254 0.90 HSD17B14 (0.44) HSD17B14MAPK1SMN1; SMN2USP2PRKCQ
SCHEMBL3467150 0.78 HSD17B14 (0.50) HSD17B14MAPK1SMN1; SMN2USP2PRKCQ
SCHEMBL4290478 0.78 HSD17B14 (0.48) HSD17B14MAPK1SMN1; SMN2USP2PRKCQ
SCHEMBL3469979 0.78 USP2 (0.52) HSD17B14MAPK1SMN1; SMN2USP2PRKCQ
SCHEMBL4301974 0.77 HSD17B14 (0.51) HSD17B14MAPK1SMN1; SMN2USP2PRKCQ
SCHEMBL3466177 0.75 HSD17B14 (0.49) HSD17B14MAPK1SMN1; SMN2USP2PRKCQ
SCHEMBL3466779 0.75 HSD17B14 (0.49) HSD17B14MAPK1SMN1; SMN2USP2PRKCQ
SCHEMBL4304173 0.75 HSD17B14 (0.47) HSD17B14MAPK1SMN1; SMN2USP2PRKCQ
Hydrochloric Acid SCHEMBL4297856 0.74 HSD17B14 (0.48) HSD17B14MAPK1SMN1; SMN2USP2PRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US claimed
EP-2265600-A1 PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS Pfizer Inc. (US) 2010-12-29 EP disclosed
WO-2009098576-A1 PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS PFIZER INC. (US) 2009-08-13 WO disclosed
WO-2009098576-A1 PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS PFIZER INC. (US) 2009-08-13 WO disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders HTR6, HTR5A, TPH1 HSD17B14 2214/4885MAPK1 1674/4885SMN1; SMN2 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.